Clear Investment Research LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Clear Investment Research LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 2,215 shares of the company’s stock after purchasing an additional 72 shares during the quarter. Johnson & Johnson accounts for 0.8% of Clear Investment Research LLC’s holdings, making the stock its 26th largest holding. Clear Investment Research LLC’s holdings in Johnson & Johnson were worth $391,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Glassy Mountain Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $35,000. Retirement Financial Solutions LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $40,000. TD Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $48,000. VitalStone Financial LLC bought a new position in Johnson & Johnson during the 4th quarter worth approximately $52,000. Finally, Iron Horse Wealth Management LLC grew its position in Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Raymond James reduced their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. Atlantic Securities cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Morgan Stanley lifted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective on the stock. Finally, Guggenheim began coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 1.4 %

NYSE JNJ opened at $154.41 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The firm has a market capitalization of $401.27 billion, a PE ratio of 32.30, a P/E/G ratio of 2.67 and a beta of 0.53. The stock’s 50 day moving average is $159.89 and its 200 day moving average is $165.86.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.67 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 3.08%. Johnson & Johnson’s payout ratio is presently 99.58%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.